Stockreport

Medicenna Presents Preclinical Data Demonstrating Anti-Tumor Activity of its Anti-PD1-IL-2 BiSKIT and Long-Acting IL-4/IL-13 Super-antagonist at Cytokines 2022

Medicenna Therapeutics Corp. - Common Shares  (MDNA) 
PDF -- Single agent Anti-PD1-IL-2 BiSKITâ„¢ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, [Read more]